Directly Contact Organization
Save Project as XML
Details |
| Project Title | Antiviral Compounds for HIV and Other Viral Infections | |
|---|---|---|
| Track Code | 27668 | |
| Website | https://techtransfer.universityofcalifornia.edu/NCD/27668.html?utm_source=AUTMGTP&utm_medium=webpage&utm_term=ncdid_27668&utm_campaign=TechWebsites | |
| Short Description | Through a screen for RNA-protein inhibitors, researchers at UCSF have identified a new class of HIV inhibitors. Following multiple rounds of medicinal chemistry and compound testing, the most advanced compounds have improved the efficacy more than two logs and are capable of inhibiting HIV replication with low-nanomolar IC50s and Therapeutic Indices >10,000. Interestingly, the pathway to drug resistance is unique with these inhibitors and we have discovered that resistant viruses are defective in an important viral gene. These findings raise the question of whether the compounds could be used to drive the viral populations towards attenuation and possibly one step closer to a functional cure. | |
| Abstract | This invention identifies a novel class of HIV inhibitors targeting RNA-protein interactions. | |
| Tags | antiviral, inhibitors, Rev, HIV, RRE, RNA-protein interactions, Disease: Infectious Diseases, New Chemical Entities, drug leads, Therapeutics | |
| Posted Date | May 27, 2017 8:42 AM | |
Advantages |
The global market for HIV drugs is around $20 billion annually. To find new and more effective HIV antivirals, scientists at UCSF have recently focused on viral regulatory complexes that perform critical functions in HIV replication and are important targets for therapeutic intervention. In HIV-infected cells, the Tat and Rev proteins form regulatory complexes with multiple viral and cellular factors to direct transcription and export of the viral RNA. Scientists have identified novel lead compounds that may disrupt the interaction between Rev and the Rev Response Element (RRE) thus preventing HIV replication. These molecules have been tested extensively in HIV replication studies in cell culture and in primary cells and represent an important step towards the development of a new class of HIV therapeutics that could eventually find a place in future HIV combination therapies.
The current invention provides the following advantages:- Low toxicity and wide therapeutic window
- New mechanism-of-action
- Used in combination with existing RT, protease or integrase inhibitors
- May be used to treat diseases caused by other viruses
Potential Applications |
Additional Information |
Looking for Partners
To develop & commercialize the technology as a therapy for HIV and other viral infections
Data Availability
In vitro data available
Related Materials
Additional Technologies by these Inventors
Tech ID/UC Case
27668/2013-151-0
Related Cases
2013-151-0
Contact Information |
Name : Shikha Sharma
Title :
Department :
Email : shikha.sharma@ucsf.edu
Phone : 415-502-1613
Address :
Principal Investigator |
Name : Robert Nakamura
Department :
Name : Mark Burlingame
Department :
Name : Alan Frankel
Department :
Name : Adam Renslo
Department :
Intellectual Property |
Patent Number : 10154992
Patent Title :
Patent Application Date :
Patent Publication Date :
Patent Issue Date : Dec 18, 2018
Patent Link : http://www.google.com/patents/US10154992